Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 130


Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.

Jamshidi M, Schmidt MK, Dörk T, Garcia-Closas M, Heikkinen T, Cornelissen S, van den Broek AJ, Schürmann P, Meyer A, Park-Simon TW, Figueroa J, Sherman M, Lissowska J, Keong GT, Irwanto A, Laakso M, Hautaniemi S, Aittomäki K, Blomqvist C, Liu J, Nevanlinna H.

Int J Cancer. 2013 May 1;132(9):2044-55. doi: 10.1002/ijc.27884. Epub 2012 Oct 25.


Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.

Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H.

Breast Cancer Res. 2009;11(6):R89. doi: 10.1186/bcr2460. Epub 2009 Dec 18.


Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.

van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK.

Breast Cancer Res Treat. 2011 Nov;130(2):599-608. doi: 10.1007/s10549-011-1615-y. Epub 2011 Jun 11.


Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI.

PLoS One. 2010 May 26;5(5):e10813. doi: 10.1371/journal.pone.0010813.


Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.

Koh WP, Van Den Berg D, Jin A, Wang R, Yuan JM, Yu MC.

Breast Cancer Res Treat. 2011 Dec;130(3):1011-9. doi: 10.1007/s10549-011-1680-2. Epub 2011 Jul 21.


MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.

Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Apr;132(3):947-53. doi: 10.1007/s10549-011-1637-5. Epub 2011 Jun 25.


Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Cheng H, Ma B, Jiang R, Wang W, Guo H, Shen N, Li D, Zhao Q, Wang R, Yi P, Zhao Y, Liu Z, Huang T.

Mol Biol Rep. 2012 Sep;39(9):9265-74. doi: 10.1007/s11033-012-1800-z. Epub 2012 Jun 24.


Association of breast cancer outcome with status of p53 and MDM2 SNP309.

Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.

J Natl Cancer Inst. 2006 Jul 5;98(13):911-9.


Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254. Epub 2011 Apr 8.


MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.

Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomäki K, Heikkilä P, Bartek J, Blomqvist C, Bützow R, Nevanlinna H.

PLoS One. 2011;6(11):e26122. doi: 10.1371/journal.pone.0026122. Epub 2011 Nov 10.


Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.

Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van't Veer LJ; Breast Cancer Association Consortium.

Cancer Res. 2007 Oct 1;67(19):9584-90.


Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.

Ann Surg Oncol. 2010 Apr;17(4):1194-202. doi: 10.1245/s10434-009-0853-2. Epub 2009 Nov 26.


Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.

Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC.

Hum Genet. 2011 Jun;129(6):663-73. doi: 10.1007/s00439-011-0957-1. Epub 2011 Feb 9.


XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.

Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V.

Anticancer Res. 2014 Jun;34(6):3031-7.


High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.

Aceto GM, Solano AR, Neuman MI, Veschi S, Morgano A, Malatesta S, Chacon RD, Pupareli C, Lombardi M, Battista P, Marchetti A, Mariani-Costantini R, Podestà EJ.

Breast Cancer Res Treat. 2010 Aug;122(3):671-83. doi: 10.1007/s10549-009-0596-6. Epub 2009 Oct 23.


The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.

Almquist LM, Karagas MR, Christensen BC, Welsh MM, Perry AE, Storm CA, Nelson HH.

Carcinogenesis. 2011 Mar;32(3):327-30. doi: 10.1093/carcin/bgq256. Epub 2010 Dec 1.


The TP53 gene polymorphisms and survival of sporadic breast cancer patients.

Bišof V, Salihović MP, Narančić NS, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Rudan P.

Med Oncol. 2012 Jun;29(2):472-8. doi: 10.1007/s12032-011-9875-2. Epub 2011 Mar 2.


Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.

Udler MS, Azzato EM, Healey CS, Ahmed S, Pooley KA, Greenberg D, Shah M, Teschendorff AE, Caldas C, Dunning AM, Ostrander EA, Caporaso NE, Easton D, Pharoah PD.

Int J Cancer. 2009 Dec 1;125(11):2687-96. doi: 10.1002/ijc.24678.


Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.

Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk